Study Demonstrates Potential for Faster Drug Development
On 12 December, FDA hosted a full day Cardiac Safety Research Consortium (CSRC) meeting to release the results of the IQ-CSRC Study demonstrating the ability to conduct robust cardiac safety characterization several years earlier than current practice in clinical development. The definitive validation of this approach included cardiac safety studies for five marketed drugs for which cardiac safety profiles are well known. The testing was performed in a study design routinely used by pharmaceutical developers to characterize the safety of new compounds when given to humans for the first time (First-in-Human studies). This validation programme used the proprietary Early Precision QT methodology developed by iCardiac Technologies to analyse the electrocardiogram (ECG) data collected in the study in a blinded way, and compare it to the known outcomes for each drug.
The results show that the Early Precision QT methodology substantially increases the data analysis precision over historical data analysis methods. This increase in precision enables moving the definitive cardiac safety testing upstream in the pharmaceutical R&D pipeline, from large and expensive studies in later phases to smaller and earlier First-in-Human studies.
In addition, this approach delivers a much lower expected incidence of inconclusive results in comparison to historical assessment methodologies. The implications for the drug development process are very significant and include the potential to reduce the cost and increase the speed and reliability of cardiac safety testing. This could reduce the over-reliance in the future on the more expensive Thorough QT (TQT) tests that have been used during the past 10 years.
“Access to more accurate cardiac safety data early in the clinical trials process can mean accelerating the development of promising drugs that might have been canceled due to inconclusive or inaccurate results from the manual assessment processes currently in use by traditional ECG core laboratories", said Alex Zapesochny, President and CEO of iCardiac Technologies. “The Early Precision QT methodology analyses more than 100 times the data when compared with traditional analysis methods, offering much earlier insights into the viability of drugs in development.”
The study, which was designed by a team including the FDA, iCardiac Technologies, and the Cardiac Safety Research Consortium, offers the potential for significant cost savings and earlier commercialization of promising new chemical entities in the immediate future.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance